Paul Tudor Jones II acquired 469k Blueprint Medicines shares worth $60.7M. That's 0.45% of their equity portfolio (24th largest holding). The first Blueprint Medicines trade was made in Q3 2016. Since then Paul Tudor Jones II bought shares eleven more times and sold shares on seven occasions. The stake costed the investor $48.5M, netting the investor a gain of 25% so far.